Sanofi-aventis U.S. (NYSE: SNY) announced the signing of an exclusive licensing agreement with Intelliject, Inc. for a novel epinephrine auto ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE